Oramed Pharmaceuticals Inc. Stock price

Equities

ORMP

US68403P2039

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
2.82 USD +3.68% Intraday chart for Oramed Pharmaceuticals Inc. -4.73% +22.08%
Sales 2024 * 1.3M Sales 2025 * - Capitalization 114M
Net income 2024 * -10M Net income 2025 * - EV / Sales 2024 * 87.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-10.8 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.77%
More Fundamentals * Assessed data
Dynamic Chart
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024 CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Oramed Pharmaceuticals Inc. Announces Resignation of Yadin Rozov from the Board of Directors CI
Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024 CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Oramed Pharmaceuticals Inc.(TASE:ORMP) dropped from TA-125 Index CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics MT
Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc. CI
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q). CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million. CI
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture MT
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally CI
Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating MT
Oramed Pharmaceuticals Says Hefei Tianhui Biotechnology Completes Phase 3 Trial of Oral Insulin; Shares Rise MT
More news
1 day+3.68%
1 week-4.73%
Current month-14.29%
1 month-21.23%
3 months+27.03%
6 months+8.88%
Current year+22.08%
More quotes
1 week
2.66
Extreme 2.66
2.93
1 month
2.65
Extreme 2.65
3.48
Current year
2.10
Extreme 2.1
3.67
1 year
1.67
Extreme 1.67
5.25
3 years
1.67
Extreme 1.67
31.54
5 years
1.67
Extreme 1.67
31.54
10 years
1.67
Extreme 1.67
31.54
More quotes
Managers TitleAgeSince
Founder 83 02-04-11
Chief Executive Officer 50 02-04-11
Chief Operating Officer 53 13-04-13
Members of the board TitleAgeSince
Chief Executive Officer 50 02-04-11
Founder 83 02-04-11
Director/Board Member 59 07-10-22
More insiders
Date Price Change Volume
24-03-27 2.82 +3.68% 160,613
24-03-26 2.72 -1.45% 88,737
24-03-25 2.76 -5.15% 167,630
24-03-22 2.91 +3.93% 68,859
24-03-21 2.8 -5.41% 141,380

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.82 USD
Average target price
4.25 USD
Spread / Average Target
+50.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Oramed Pharmaceuticals Inc. - Nasdaq